Amgen reported strong Q3 2008 results, exceeding expectations with 7% revenue growth and raising both revenue and EPS guidance for the year. Management expressed optimism about the company's performance and future prospects, highlighting a robust pipeline, successful product launches like Nplate, and encouraging clinical results for denosumab. This positive performance and upbeat outlook are likely to boost investor confidence and support a rally in the stock price in the short term.

[2]